{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T03:42:30Z","timestamp":1649130150160},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s40121-013-0016-4","type":"journal-article","created":{"date-parts":[[2013,10,21]],"date-time":"2013-10-21T07:23:03Z","timestamp":1382340183000},"page":"209-215","source":"Crossref","is-referenced-by-count":5,"title":["Stable Susceptibility to Aminoglycosides in an Age of Low Level, Institutional Use"],"prefix":"10.1007","volume":"2","author":[{"given":"John A.","family":"Bosso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha L.","family":"Haines","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juanmanuel","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,22]]},"reference":[{"key":"16_CR1","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1001\/archinte.168.20.2254","volume":"168","author":"AL Pakyz","year":"2008","unstructured":"Pakyz AL, MacDougall C, Oinonen M, Polk RE. Trends in antibacterial use in US academic health centers: 2002\u20132006. Arch Intern Med. 2008;168:2254\u201360.","journal-title":"Arch Intern Med"},{"key":"16_CR2","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1086\/665724","volume":"33","author":"M Ababneh","year":"2012","unstructured":"Ababneh M, Harpe S, Oinonen M, Polk RE. Trends in aminoglycoside use and gentamicin-resistant Gram-negative clinical isolates in US academic medical centers: implications for antimicrobial stewardship. Infect Control Hosp Epidemiol. 2012;33:594\u2013601.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"16_CR3","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1128\/AAC.35.7.1284","volume":"35","author":"DN Gerding","year":"1991","unstructured":"Gerding DN, Larson TA, Hughes RA, Weiler M, Shanholtzer C, Peterson LR. Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital. Antimicrob Agents Chemother. 1991;35:1284\u201390.","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR4","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/infdis\/141.3.338","volume":"141","author":"RA Weinstein","year":"1980","unstructured":"Weinstein RA, Nathan C, Gruensfelder R, Kabins SA. Endemic aminoglycoside resistance in Gram-negative bacilli: epidemiology and mechanisms. J Infect Dis. 1980;141:338\u201345.","journal-title":"J Infect Dis"},{"key":"16_CR5","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1056\/NEJMra041359","volume":"352","author":"GA Jacoby","year":"2005","unstructured":"Jacoby GA, Munoz-Price LS. The new \u03b2-lactamases. N Engl J Med. 2005;352:280\u201391.","journal-title":"N Engl J Med"},{"key":"16_CR6","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1086\/671003","volume":"34","author":"P Savard","year":"2013","unstructured":"Savard P, Carroll KC, Wilson LE, Perl TM. The challenges of carbapenemase-producing Enterobacteriaceae and infection prevention: protecting patients in the chaos. Infect Control Hosp Epidemiol. 2013;34:730\u20139.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"S1","key":"16_CR7","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1086\/655996","volume":"31","author":"AJ Kallen","year":"2010","unstructured":"Kallen AJ, Srinivasan A. Current epidemiology of multidrug-resistant Gram-negative bacilli in the United States. Infect Control Hosp Epidemiol. 2010;31(S1):S51\u20134.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"5","key":"16_CR8","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1128\/AAC.49.5.2137-2139.2005","volume":"49","author":"MJ Schwaber","year":"2005","unstructured":"Schwaber MJ, Navon-Venezia S, Schwartz D, Carmeli Y. High levels of antimicrobial coresistance among extended-spectrum-\u03b2-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2005;49(5):2137\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"16_CR9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.diagmicrobio.2006.07.011","volume":"57","author":"R Colodner","year":"2007","unstructured":"Colodner R, Samra Z, Keller N, et al. First national surveillance of susceptibility of extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella spp. to antimicrobials in Israel. Diagn Microbiol Infect Dis. 2007;57(2):201\u20135.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"16_CR10","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/jac\/dkn469","volume":"63","author":"L Leibovici","year":"2009","unstructured":"Leibovici L, Vidal L, Paul M. Aminoglycoside drugs in clinical practice: an evidence-based approach. J Antimicrob Chemother. 2009;63:246\u201351.","journal-title":"J Antimicrob Chemother"},{"key":"16_CR11","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1089\/sur.2007.080","volume":"10","author":"EW Mueller","year":"2009","unstructured":"Mueller EW, Boucher BA. The use of extended-interval aminoglycoside dosing strategies for the treatment of moderate-to-severe infections encountered in critically ill surgical patients. Surg Infect. 2009;10:563\u201370.","journal-title":"Surg Infect"},{"key":"16_CR12","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1128\/AAC.01314-10","volume":"55","author":"GL Drusano","year":"2011","unstructured":"Drusano GL, Ambrose P, Louie A. Optimization of aminoglycoside therapy. Antimicrob Agents Chemother. 2011;55:2528\u201331.","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR13","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Analysis and presentation of cumulative antimicrobial susceptibility test data. 3rd ed. Approved guideline M39-A3. Wayne, PA: CLSI; 2009."},{"key":"16_CR14","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1128\/JCM.01716-06","volume":"45","author":"S Juretschko","year":"2007","unstructured":"Juretschko S, LaBombardi VJ, Lerner SA, Sreckenberger PC. Accuracies of \u03b2-lactam susceptibility test results for Pseudomonas aeruginosa with four automated systems (BD Phoenix, MicroScan WalkAway, Vitek and Viteck 2). J Clin Microbiol. 2007;45:1339\u201342.","journal-title":"J Clin Microbiol"},{"key":"16_CR15","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s00253-005-0279-0","volume":"70","author":"S Jana","year":"2006","unstructured":"Jana S, Deb JK. Molecular understanding of aminoglycoside action and resistance. Appl Microbiol Biotechnol. 2006;70:140\u201350.","journal-title":"Appl Microbiol Biotechnol"},{"key":"16_CR16","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1128\/AAC.01131-09","volume":"43","author":"KM Wener","year":"2010","unstructured":"Wener KM, Schechner V, Gold HS, Wright SB, Carmeli Y. Treatment with fluoroquinolones or with \u03b2-lactam-\u03b2-lactamase inhibitor combinations is a risk factor for isolation of extended-spectrum-\u03b2-lactamase-producing Klebsiella species in hospitalized patients. Antimicrob Agents Chemother. 2010;43:2010\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR17","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.diagmicrobio.2009.08.020","volume":"65","author":"PR Rhomberg","year":"2009","unstructured":"Rhomberg PR, Jones RN. Summary trends for the meropenem yearly susceptibility test information collection program: a 10-year experience in the United States (1999\u20132008). Diagn Microbiol Infect Dis. 2009;65:414\u201326.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"16_CR18","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1086\/591861","volume":"29","author":"AI Hidron","year":"2008","unstructured":"Hidron AI, Edwards JR, Patel J, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006\u20132007. Infect Control Hosp Epidemiol. 2008;29:996\u20131011.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"16_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0002-9343(85)90184-6","volume":"79","author":"DN Gerding","year":"1985","unstructured":"Gerding DN, Larson TA. Aminoglycoside resistance in gram-negative bacilli during increased amikacin use. Comparison of experience in 14 United States hospitals with experience in the Minneapolis Veterans Administration Medical Center. Am J Med. 1985;79:1\u20137.","journal-title":"Am J Med"},{"key":"16_CR20","doi-asserted-by":"crossref","first-page":"219","DOI":"10.7326\/0003-4819-100-2-219","volume":"100","author":"RF Betts","year":"1984","unstructured":"Betts RF, Valenti WM, Chapman SW, et al. Five-year surveillance of aminoglycoside usage in a university hospital. Ann Intern Med. 1984;100:219\u201322.","journal-title":"Ann Intern Med"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-013-0016-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T00:16:00Z","timestamp":1498090560000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40121-013-0016-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,22]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["16"],"URL":"https:\/\/doi.org\/10.1007\/s40121-013-0016-4","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,22]]}}}